New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
08:18 EDTTEVA, MNTA, MYL, NVSMomenta Pharma rises after high court rejects Copaxone delay bid
Shares of Momenta Pharmaceuticals (MNTA) are higher in pre-market trading after the Supreme Court denied Teva's (TEVA) request to delay the launch of generic forms of its relapsing-remitting multiple sclerosis product, Copaxone. WHAT'S NEW: Teva confirmed on April 19 that the Chief Justice of the United States denied the company's application for an injunction seeking to prevent the launch of a generic version of Copaxone. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for Copaxone, the company said. WHAT'S NOTABLE: Momenta has developed a generic version of Copaxone in partnership with Novartis' (NVS) Sandoz unit. Mylan, which is preparing to launch a generic version of Copaxone as well, said after the ruling: "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. FDA on May 25, 2014." PRICE ACTION: In pre-market trading, Momenta shares are up over 12% to $12.46, while Mylan shares are up more than 3% to $48.48. Teva shares trading in New York are down about 1.7% to $50 in pre-market trading.
News For MNTA;NVS;MYL;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
05:56 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Subscribe for More Information
August 25, 2015
17:11 EDTTEVAU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
15:02 EDTMYL, TEVA, MNTA, NVSMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTTEVA, MYL, MNTATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYL, TEVATeva to refrain from voting at Mylan special meeting
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
August 24, 2015
13:15 EDTNVSFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
12:11 EDTNVSNovartis announces FDA approves expanded use for Promacta
Subscribe for More Information
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
05:25 EDTNVSNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 20, 2015
07:31 EDTMNTAMomenta shares offer 'significant opportunity,' says Bernstein
Bernstein analyst Ronny Gal sees a "significant opportunity" in shares of Momenta Pharmaceuticals over the next few months. Copaxone sales should prove durable as a competing approval is unlikely until mid-2016, Gal tells investors in a research note. The analyst sees limited share downside before year-end and raised his price target for the stock to $31. He keeps an Outperform rating on Momenta.
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
05:29 EDTNVSNovartis Odomzo gains EU approval for laBCC
Subscribe for More Information
August 19, 2015
10:05 EDTMNTAHigh option volume stocks
High option volume stocks: MNTA TUR ITB CLR HILL DV AU XLNK AEO CYBR
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use